Table 1. Baseline costs, risks and utility values of icotinib and gefitinib in advanced NSCLC patients in China.

Data are in 2014 US dollars.

Parameter	Base case	Range	Source
Drug costs ($ 21 days/one unit)
Icotinib	1,349.40	1349.40	Market
Gefitinib	1,818.48	1610.90	Lognormal
Routine follow-up of patients per unit[15]	57.96	50.64	Lognormal
Docetaxel, 1 ampule at 20mg[15]	108.72	74.96	Local
Costs of ADRs ($)
Diarrhea	5.18	4.14/6.22	±20%
Nausea	13.61	10.89/16.33	±20%
Rash	5.50	4.4/6.6	±20%
Raised aminotransferase	216.35	173.08/259.62	±20%
Probability of serious ADR events(%)			[12]
Diarrhoea	2	1.4	±30%
Rash	1	0.7	±30%
Raised	0.5	0.35	±30%
Raised	1	0.7	±30%
Rash	0.5	0.35	±30%
Nausea	0.5	0.35	±30%
Utility values
PFS on oral therapy[20]	0.673	0.27/0.80
DP [20]	0.473	0.19/0.56
Diarrhoea in gefitinib group [20]	0.606	0.24/0.73
Rash in gefitinib group[20]	0.621	0.25/0.74
Rash in icotinib group [20]	0.621	0.25/0.74
Nausea in icotinib group[20]	0.605	0.543/0.571
Discount rate(%)[21]	3	0/8	Fixed in PSA

Abbreviation: NSCLC, non-small cell lung cancer; ADR: adverse drug reaction; PFS, progression free survival; DP, disease progression, PSA = Probabilistic sensitivity analysis.